GlassScriptPhysician profile
Hongsheng Wei
NPI 1689694580
$11,275.51
in general payments reported to CMS, 2019-2025
29 companies · $756 in 2025
The $756 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,874 · 2020: $1,568 · 2021: $2,742 · 2022: $1,533 · 2023: $1,386 · 2024: $1,418 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,558.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,844.58 | 2019-2025 | Linzess, Viberzi, Creon |
| Astrazeneca Pharmaceuticals LP | $1,797.70 | 2019-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $946.10 | 2020-2024 | Xarelto |
| Amgen INC. | $650.64 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $641.89 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $556.25 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $432.47 | 2019-2024 | Trintellix |
| Pfizer INC. | $412.00 | 2019-2025 | |
| Almatica Pharma LLC | $390.32 | 2021-2024 | Loreev Xr, Teriparatide, Gralise |
| Glaxosmithkline, LLC. | $390.04 | 2019-2025 | Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $384.13 | 2019-2023 | Linzess |
| Allergan, INC. | $373.86 | 2019-2020 | |
| Abbott Laboratories | $369.17 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $363.93 | 2020-2022 | |
| Amarin Pharma, INC. | $354.48 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.96 | 2019-2024 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $272.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $237.04 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.98 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $98.77 | 2020-2021 | |
| Lilly USA, LLC | $85.98 | 2019-2025 | Jardiance, Mounjaro |
| Biogen, INC. | $43.37 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $39.14 | 2020-2021 | |
| Genentech USA, INC. | $38.65 | 2020-2021 | |
| Eisai INC. | $38.56 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.05 | 2019 | |
| Eyevance Pharmaceuticals LLC | $22.27 | 2021 | |
| Redhill Biopharma INC. | $16.04 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hongsheng Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.